Monografias.com > Sin categoría
Descargar Imprimir Comentar Ver trabajos relacionados

Tumores retroperitoneales primitivos del adulto (página 3)




Enviado por pablo



Partes: 1, 2, 3

  • 6. Lahey FH, Ackerson EB. Retroperitoneal
    cysts. Ann Surg. 1934;100:231-237.

  • 7. Fletcher C, Unni KK, Mertens F. WHO
    Classification of Soft Tissue Tumors. In: Fletcher C, Unni
    KK, Mertens F, editors. Pathology and Genetics: Tumors of
    Soft Tissue and Bone. World Health Organization
    Classification of Tumors. International Agency for Research
    on Cancer Press; 2002. p. 9-12.

  • 8. Greene FL, Page DL, Fleming FD, Fritz A,
    Balch CM, Haller DG, Morrow M, editores. American Joint
    Committee on Cancer: Cancer Staging Manual. 6.a ed. New York:
    Springer; 2002. p. 221-6.

  • 9. Spencer Liles J, Ching Wei D Tzeng, Joshua J
    Short, Kulesza P, Heslin MJ. Retroperitoneal and
    Intraabdominal Sarcoma. Curr Probl Surg.
    2009;46:445-503.

  • 10. De Schepper AM, Bloem JL. Soft Tissue
    Tumors. Grading, Staging and Tissue – Specific Diagnosis. Top
    Magn Reson Imaging. 2007; 18: 431-444.

  • 11. Hueman MT, Ahuja N. Soft tissue sarcoma,
    Surg Clin N Am. 2008; 88: 451-680.

  • 12. Voros D, Theodorou D, Ventouri K,
    Prachalias A, Danias N, Gouliamos A. Retroperitoneal Tumors:
    Do the satellite Tumors Mean Something? Journal of Surgical
    Oncology, 1998; 68: 30 – 33.

  • 13. Fletcher C, The evolving classification of
    soft tissue tumors: an update based on the new WHO
    classification. Histopatology. 2006; 48:
    3-12.

  • 14. Fadul D, Fayad LM. Advanced modalities for
    the imaging of sarcoma. Surg Clin N Am. 2008; 88:
    521-537.

  • 15. Verdugo MA. Ultrasonido en el estudio de
    tumores de partes blandas. Rev Chil Radiol. 2009;15:
    5-18.

  • 16. Cogbill TH, Jarman BT. Diagnostic Imaging
    for General Surgeon. Surg Clin N Am. 2011; 91:
    1-276.

  • 17. Nishino M, Hayakawa K, Minami M, Yamamoto
    A, Ueda H, Takasu K. Primary retroperitoneal neoplasms: CT
    and MR imaging findings with anatomic and pathologic
    diagnostic clues. RadioGraphics 2003; 23: 45-57.

  • 18. Francis IR, Cohan RH, Varma DG, Sondak VK.
    Retroperitoneal sarcomas. Cancer Imaging .2005; 5: 89 –
    94.

  • 19. Kilkenny JW III, Bland KI, Copeland EM III:
    Retroperitoneal sarcoma: The University of Florida
    experience. J Am Coll Surg. 1996; 182: 329-339.

  • 20. Van Rijswijk CSP, Kunz P, Hogendoorn PCW,
    Taminiau AHM, Doornbos J, Bloem JL. Diffusion-Weighted MRI in
    the Characterization of Soft-Tissue Tumors. J Magn Reson
    Imaging. 2002; 15: 302-307.

  • 21. Schnapauff D, Zeile M, Ben Niederhagen M,
    Fleige B, Tunn Per-Ulf, Hamm B, Dudeck O. Diffusion-Weighted
    Echo-Planar Magnetic Resonance Imaging for the Assessment of
    Tumor Cellularity in Patients With Soft-Tissue Sarcomas.
    Journal of Magnetic Resonance Imaging. 2009; 29:
    1355-59.

  • 22. Coindre JM. Immunohistochemistry in the
    diagnosis of soft tissue tumous. Histopathology. 2003; 43:
    1-16.

  • 23. Ordoñez JL, Osuna D,
    Garcia-Dominguez DJ, Amaral AT, Otero-Motta AP, Mackintosch
    C, et al. The clinical relevance of molecular genetics in
    soft tissue sarcomas. Adv Anat Pathol. 2010; 17:
    162-181.

  • 24. Álava E de. Patologia Molecular de
    los Sarcomas. Oncologia. 2005; 28: 426 – 442.

  • 25. Tolcher AW, Sarantopoulos J, Patnaik A,
    Phase I, pharmacokinetic and pharmacodynamic study of AMG
    479, a fully human monoclonal antibody to insulin-like growth
    factor receptor 1. J Clin Oncol. 2009; 27:
    5800-5807

  • 26. Ambrosini G, Cheema HS, Seelman S,
    Sorafenib inhibits growth and mitogen-activated protein
    kinase signaling in malignant peripheral nerve sheath cells.
    Mol Cancer Ther. 2008;7:890-896.

  • 27. Maki RG, D`Adamo DR, Keohan ML, Phase II
    study of sorafenib in patients with metastatic or recurrent
    sarcomas. J Clin Oncol. 2009;27:3133-3140.

  • 28. Hensley ML, Sill MW, Scribner DR Jr,
    Sunitinib malate in the treatment of recurrent or persistent
    uterine leiomyosarcoma: a Gynecologic Oncology Group phase II
    study. Gynecol Oncol. 2009; 115: 460-465.

  • 29. George S, Merriam P, Maki RG, Multicenter
    phase II trial of sunitinib in the treatment of
    nongastrointestinal stromal tumor sarcomas. J Clin Oncol.
    2009;27:3154-3160.

  • 30. Yuan R, Kay A, Berg WJ, Targeting
    tumorigenesis: development and use of mTOR inhibitors in
    cancer therapy. J Hematol Oncol. 2009;2:45.

  • 31. Ordonez JL, Martins AS, Osuna D, Targeting
    sarcomas: therapeutic targets and their rational. Semin Diagn
    Pathol. 2008;25:304-316.

  • 32. Muller CR, Paulsen EB, Noordhuis P,
    Potential for treatment of liposarcomas with the MDM2
    antagonist Nutlin-3A. Int J Cancer.
    2007;121:199-205.

  • 33. Raut Ch, Pisters P, Retroperitoneal
    Sarcomas: Combined – Modality Treatment Approaches. J Surg
    Oncol. 2006; 94 : 81 – 87.

  • 34. Hueman MT, Herman JM, Ahuja N. Management
    of Retroperitoneal Sarcomas. Surg Clin N Am. 2008; 88:
    583-597.

  • 35. Lewis JJ, Leung D, Woodruff JM, Brennan MF.
    Retroperitoneal Soft – Tissue Sarcoma. Analysis of 500
    Patients Treated and Followed at a Single Institution. Ann
    Surg. 1998;228:355-365.

  • 36. Grimer R, Judson I, Peake D, Seddon B.
    Guidelines for the management of soft tissue sarcomas.
    Sarcomas. 2010; 15: 1-15.

  • 37. Stojadinovic A, Leung DHY, Hoss A, Jaques
    DP, Lewis JJ, Brennan MF, Analisis of the prognostic
    significance of microscopic margins in 2084 localized primary
    adult soft tissue sarcomas. Ann Surg. 2002; 235:
    424-434.

  • 38. Stoeckle E, Coindre JM, Bonvalot S, et al.
    Prognostic factors in retroperitoneal

  • sarcoma: a multivariate analysis of a series of 165
    patients of the French Cancer Center Federation Sarcoma Group.
    Cancer. 2001;92:359-68.

    • 39. Ferrario T, Karakousis CP. Retroperitoneal
      Sarcomas. Arch Surg. 2003; 38:248-251.

    • 40. Dalton RR, Donohue JH, Mucha P Jr, van
      Heerden JA, Reiman HM, Chen SP. Management of retroperitoneal
      sarcomas. Surgery. 1989; 4: 725-732.

    • 41. Catton Ch N, O`Sullivan B, Kotwall C,
      Cummings B, Hao Y, Fornasier V. Outcomes and prognosis in
      retroperitoneal soft tissue sarcoma. International Journal of
      Radiation Oncology. 1994; 29: 1005-1010.

    • 42.  Singer S, Corson JM, Demetri GD, Healey
      EA, Marcus K, Eberlein TJ. Prognostic factors predictive of
      survival for truncal and retroperitoneal soft-tissue sarcoma.
      Ann Surg. 1995;221:185-95.

    • 43. Van Doom RC, Gallee MP, Hart AA, Gortzak E,
      Rutgers EJ, van Coevorden F, Keus RB, Zoetmulder FA.
      Resecable retroperitoneal sof tissue sarcomas. The effect of
      extent of resection and postoperative radiation therapy on
      local tumor control. Cancer. 1994;73: 637-642.

    • 44. Storm FK, Eilber FR, Mirra J, Morton DL.
      Retroperitoneal sarcomas: a reappraisal of treatment. Journal
      of Surgical Oncology. 1981; 17: 1-7.

    • 45. Jaques DP, Coit DG, Hajdu SI, Brennan MF,
      Management of Primary and Recurrent Soft tissue Sarcoma of
      the Retroperitoneum. Ann Surg. 1990; 212:
      51-59.

    • 46. Malerba M, Battista G, Pacelli F, Carriero
      C, Caprino P, Piccioni E, Crucitti P, Crucitti F. Primary
      Retroperitoneal Soft Tissue Sarcomas: Results of aggressive
      surgical treatment. World J Surg 1993; 23:
      670-675.

    • 47. Karakousis CP, Kontzoglu K, Driscoll DL.
      Resecability of retroperitoneal sarcomas: a matter of
      surgical technique? Eur J Surg Oncol. 1995; 21:
      617-622.

    • 48. Mc Grath PC. Retroperitoneal sarcomas.
      Semin Surg Oncol. 1994;10:364-8.

    • 49. Shibata D, Lewis JJ, Leung DH, Brennan MF.
      Is there a role for incomplete resection in the management of
      retroperitoneal liposarcomas? JAm Coll Surg.
      2001;193:373-9.

    • 50. Strauss DC, Hayes AJ, Thway K, Moskovic EC,
      Fisher C, Thomas JM. Surgical management of primary
      retroperitoneal sarcoma. British Journal of Surgery 2010; 97:
      698 – 706.

    • 51. Marin Gomez LM, Vega Ruiz V, Garcia
      Ureña MA. Sarcomas Retroperitoneales. Aportacion de
      cinco nuevos casos y revisión de la situación
      actual. Cir Esp. 2007; 82:172-176.

    • 52. Anaya DA, Lev DC, Pollock RE, The role of
      surgical margin status in retroperitoneal sarcoma. J Surg
      Oncol. 2008;98:607-610.

    • 53. Gronchi A, Casali PG, Fiore M, Mariani L,
      Lo Vullo S, Bertulli R, et al. Retroperitoneal Soft Tissue
      Sarcomas. Patterns of Recurrence in 167 Patients Treated at a
      Single Institution. Cancer. 2004; 100: 2448 –
      2455.

    • 54. Bonvalot S, Rivoire M, Castaing M, Stoeckle
      E, Le Cesne A, Blay JY, Laplanche A. Primary retroperitoneal
      sarcomas: a multivariate analysis of surgical factors
      associated with local control. J Clin Oncol. 2009; 27:
      31.37.

    • 55. Virseda Rodriguez JA, Donate Moreno MJ,
      Pasto Navarro H, Carrion Lopez P, Martinez Ruiz J, Martinez
      Sanchiz C, Peran Teruel M. Tumores Retroperitoneales
      Primarios. Revisión de nuestros casos de los
      últimos diez años. Arch Esp Urol.
      2010;63:13-22.

    • 56. Gronchi A, Lo Vullo S, Fiore M, Musi Ch,
      Stacchiotti S, Collini P, et al. Aggressive surgical policies
      in a retrospectively reviewed single-institution case series
      of retroperitoneal soft tissue sarcoma patients. J Clin
      Oncol. 2009;27:24-30.

    • 57. Schwarzbach MHM, Hormann Y, Hinz U,
      Leowardi Ch, Bückler D, Mechtersheimer G, et al.
      Clinical results of surgery for retroperitoneal sarcoma with
      major blood vessel involvement. J Vasc Surg.
      2006;44:46-55.

    • 58. Medina-Villaseñor EA,
      Martinez-Macias R, Diaz-Rodriguez L, Barra-Martinez R, de la
      Garza-Navarro JM, Quezada-Adame I, Neyra-Ortiz E. Sarcomas
      retroperitoneales. Cir Gen 2006;28:77-82.

    • 59. Fong Y, Coit DG, Woodruff JM, Brennan MF.
      Lymph node metastasis from soft tissue sarcoma in adults.
      Analysis of data from a prospective database of 1772 sarcoma
      patients. Ann Surg. 1993; 217: 72-7.

    • 60. Van Geel AN, Pastorino U, Jauch KW, Judson
      IR, van Coevorden F, Buesa JM, et al. Surgical treatment of
      lung metastases: The European Organization for Research and
      Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study
      of 255 patients. Cancer 1996; 77: 675-682.

    • 61. Sindelar WF, Kinsella TJ, Chen
      PW, DeLaney TF, Tepper JE, Rosenberg SA, et al.

    Intraoperative radiotherapy in
    retroperitoneal sarcomas. Final results of a
    prospective,

    randomized, clinical trial. Arch Surg
    1993;128:402-410.

    • 62. Pawlik TM, Pisters PWT, Mikula L, Feig BW,
      Hunt KK, Cormier JN, et al. Long-term results of two
      prospective trials of preoperative external beam radiotherapy
      for localized intermediate- or high-grade retroperitoneal
      soft tissue sarcoma. Ann Surg Oncol.
      2006;13:508-17.

    • 63. Pisters PW, O"Sullivan B. Retroperitoneal
      sarcomas: combined modality treatment approaches. Curr Opin
      Oncol. 2002;14:400-5.

    • 64. Jones JJ, Catton CN, O`Sullivan B, Couture
      J, Heisler RL, Kandel RA, et al. Initial results of a trial
      of preoperative external-beam radiation therapy and
      postoperative brachytherapy for retroperitoneal sarcoma. Ann
      Surg Oncol 2002;9:346-354.

    • 65. Petersen IA, Haddock MG, Donohue JH,
      Nagorney DM, Grill JP, Sargent DJ, et al. Use of
      intraoperative electron beam radiotherapy in the management
      of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol
      Biol Phys 2002; 52:469-475.

    • 66. Gieschen HL, Spiro IJ, Suit HD, Ott MJ,
      Rattner DW, Aucukiewicz ,et al. Long-term results of
      intraoperative electron beam radiotherapy for primary and
      recurrent retroperitoneal soft tissue sarcoma. Int J Radiat
      Oncol Biol Phys 2001;50:127-131.

    • 67. Tzeng CW, Fiveash JB, Popple RA, Arnoletti
      JP, Russo SM, Urist MM et al. Preoperative radiation therapy
      with selective dose escalation to the margin at risk for
      retroperitoneal sarcoma. Cancer 2006;107:371-379.

    • 68. White JS, Biberdorf D, Difrancesco LM,
      Kurien E, Temple W. Use of tissue expanders and preoperative
      external beam radiotherapy in the treatment of
      retroperitoneal sarcoma. Ann Surg Oncol
      2007;14:583-590.

    • 69. Zlotecki RA, Katz TS, Morris CG, Lind DS,
      Hochwald SN. Adjuvant radiation therapy for resecable
      retroperitoneal soft tissue sarcoma: the University of
      Florida experience. Am J Clin Oncol
      2005;28:310-316.

    • 70. Heslin MJ, Lewis JJ, Nadler E, Newman E,
      Woodruff JM, Casper ES, et al. Prognostic factors associated
      with long-term survival for retroperitoneal sarcoma:
      implications for management. J Clin Oncol.
      1997;15:2832-9.

    • 71. Gilbeau L, Kantor G, Stoeckle E, Lagarde P,
      Thomas L, Kind M, et al. Surgical resection and radiotherapy
      for primary retroperitoneal sof tissue sarcoma. Radiotherapy
      and Oncology. 2002 ;65 :137-143.

    • 72. Kaushal A, Citrin D. The Role of Radiation
      Therapy in the Management of Sarcomas. Surg Clin N Am. 2008;
      88: 629 – 646.

    • 73. Thornton K. Chemoterapeutic management of
      soft tissue sarcoma. Surg Clin N Am. 2008;88:
      647-660.

    • 74. Hensley ML, Maki R, Venkatraman E, Geller
      G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel
      in patients with unresectable lieomyosarcoma: results of a
      phase II trial. J Clin Oncol. 2002;20:2824-31.

    • 75. Maki RG. Gemcitabine and Docetaxel in
      metastatic sarcoma: past, present and future. The Oncologist.
      2007;12:999-1006.

    • 76. Stojadinovic A, Leung DHY, Hoss A, Jaques
      DP, Lewis JJ, Brennan MF. Analisis of the prognostic
      significance of microscopic margins in 2084 localized primary
      adult soft tissue sarcomas. Ann Surg.
      2002;235:424-434.

    • 77. van Dalen T, Hoekstra HJ, van Geel AN, van
      Coevorden F. Dutch Soft Tissue Sarcoma Group. Locoregional
      recurrence of retroperitoneal soft tissue sarcoma: second
      chance of cure forselected patients. Eur J Surg
      Oncol.
      2001;27:564 -568.

    • 78. Hassan I, Park SZ, Donohue JH, Operative
      Management of Primary Retroperitoneal Sarcomas. A Reappraisal
      of an Institutional Experience. Ann Surg. 2004;
      239:244-250.

    • 79. Bonvalot S, Vanel D, Terrier P, et al.
      Traitement des récidives des sarcomes
      retro-péritonéaux. Bull Cancer.
      2004;91:845-852.

    • 80. van Dalen T, Hennipman A, Van Coevorden F,
      Hoekstra HJ, van Geel BN, Slootweg P. Evaluation of a
      clinically aplicable post-surgical classification system for
      primary retroperitoneal sofa-tissue sarcoma. Ann Surg Oncol.
      2004;11:485-90.

    • 81. Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D,
      Pisters PW, et al. Establishing prognosis in retroperitoneal
      sarcoma: a new histology-based paradigm. Ann Surg Oncol.
      2009;16:667-675.

    • 82. Bautista N, SuW, O"Connell TX.
      Retroperitoneal soft-tissue sarcomas: prognosis and treatment
      of primary and recurrent disease. Am Surg
      2000;66:832-6.

    • 83. Chiappa A, Zbar AP, Biffi R, Bellomi M,
      Orecchia R, Marsiglia H, et al. Primary and recurrent
      retroperitoneal sarcoma: factors affecting survival and
      long-term outcome. Hepatogastroenterology
      2004;51:1304-1309.

    • 84. Erzen D, Sencar M, Novak J. Retroperitoneal
      sarcoma: 25 years of experience with aggressive surgical
      treatment at the Institute of Oncology, Ljubljana. J Surg
      Oncol 2005;91:1-9.

    • 85. Pacelli F, Tortorelli AP, Rosa F, Papa V,
      Bossola M, Sanchez AM, et al. Retroperitoneal soft tissue
      sarcoma: prognostic factors and therapeutic approaches.
      Tumori. 2008;94:497-504.

    • 86. Gholami S, Jacobs CD, Kapp DS,
      Parast LM, Norton JA. The value of surgery for
      retroperitoneal sarcoma. Sarcoma 2009;2009: 605840. Epub 2009
      Oct 8.

    • 87. Lehnert T, Cardona S, Hinz U, Willeke, F,
      Mechtersheimer G, Treiber M, et al. Primary and locally
      recurrent retroperitoneal soft-tissue sarcoma: local control
      and survival. Eur J Surg Oncol 2009;35:986-993.

    • 88. Grobmyer SR, Wilson JP, Apel B, Knapik J,
      Copeland E, Bland K et al. Recurrent retroperitoneal sarcoma:
      impact of biology and therapy on outcomes. J Am Coll Surg.
      2010;210:602-610.

    • 89. Mendenhall WM, Zlotecki RA, Hochwald SN,
      Hemming AW, Grobmyer SR, Cance WG. Retroperitoneal soft
      tissue sarcoma. Cancer. 2005;104:669-75.

    • 90. Xu YH, Guo KJ, Guo RX, Ge CL, Tian YL, He
      SG. Surgical management of 143 patients with adult primary
      retroperitoneal tumor. World J Gastroenterol 2007; 13:
      2619-2621.

    • 91. Windham TC, Pisters PWT. Retroperitoneal
      sarcomas. Cancer Control. 2005;12:36-43.

    • 92. Potter DA, Glenn J, Kinsella T, et al.
      Patterns of recurrence in patients with high-grade
      soft-tissue sarcomas. J Clin Oncol. 1985;3:
      353-66.

    • 93. Avancès Ch, Mottet N, Mahatmat A.
      Prognostic factors for first recurrence in patients with
      retroperitoneal sarcomas. Urologic Oncology: Seminars and
      Original Investigations. 2006;24:94-96.

    • 94. Anaya D, Lahat G, Liu J, Xing Y, Cormier
      JN, Pisters PW, et al. Multifocalidad in retroperitoneal
      sarcoma. A prognostic factor critical to surgical
      decisión-making. Ann Surg.
      2009;249:137-142.

    • 95. Cheifetz R, Catton C, Kandel R, O"Sullivan
      B, Couture J, Swallow C. Recent progress in the management of
      retroperitoneal sarcoma. Sarcoma. 2001;5:17-26.

    • 96. Echenique-Elizondo M,
      Amondarain-Arratíbel JA. Liposarcoma retroperitoneal
      gigante. Cir Esp. 2005;77:293-5.

    Anexos

    Anexo 1. Clasificación OMS /
    2002, tumores partes blandas.

    Tejido adiposo

    • Benigno

    ICD-O (726)*

    Lipoma

    8850/0

    Lipomatosis

    8850/0

    Lipomatosis del
    nervio(nerviosa)

    8850/0

    Lipoblastoma-lipoblastomatosis

    8881/0

    Angiolipoma

    8861/0

    Myolipoma

    8890/0

    Lipoma condroide

    8862/0

    Angiomyolipoma extrarenal

    8860/0

    Myelolipoma extra adrenal

    8870/0

    Células fusiformes –
    pleomorfico

    8857/0

    Hibernoma

    8880/0

    • Intermedio (localmente
      agresivo)

    Tumor lipomatoso atípico /
    liposarcoma bien diferenciado

    8851/3

    • Maligno

    Liposarcoma
    desdiferenciado

    8858/3

    Liposarcoma mixoide

    8852/3

    Liposarcoma células
    redondas

    8853/3

    Liposarcoma pleomorfico

    8854/3

    Liposarcoma tipo mixto

    8855/3

    Liposarcoma sin otra
    especificación

    8850/3

    Tumor fibroblastico –
    myofibroblastico

    • Benigno

    Fascitis nodular

    Fascitis proliferativa

    Myositis proliferativa

    Myositis osificante

    Fascitis isquémica

    Elastofibroma

    8820/0

    Hamartoma fibroso de la
    infancia

    Myofibroma/myofibromatosis

    8824/0

    Fibromatosis colli

    Fibromatosis hialina
    juvenil

    Fibromatosis de cuerpos de
    inclusión

    Fibroma vaina tendinosa

    8810/0

    Fibroblastoma
    desmoplastico

    8810/0

    Myofibroblastoma tipo
    mamario

    8825/0

    Fibroma calcificante
    aponeurótico

    8810/0

    Angiomyofibroblastoma

    8826/0

    Angiofibroma celular

    9160/0

    Fibroma tipo nucal

    8810/0

    Fibroma Gardner

    8810/0

    Tumor fibroso calcificante

    Angiofibroma células
    gigantes

    9160/0

    • Intermedio (localmente
      agresivo)

    Fibromatosis superficial (plantar –
    palmar)

    8821/1

    Fibromatosis tipo desmoide

    Lipofibromatosis

    • Intermedio (raramente
      metastizante)

    Tumor fibroso solitario y
    hemangiopericitoma

    8815/1 – 9150/1

    Tumor myofibroblastico
    inflamatorio

    8825/1

    Sarcoma myofibroblastico bajo
    grado

    8825/3

    Sarcoma fibroblastico
    mixoinflamatorio

    8811/3

    Fibrosarcoma infantil

    8814/3

    • Maligno

    Fibrosarcoma del adulto

    8810/3

    Mixofibrosarcoma

    8811/3

    Sarcoma fibromixoide de bajo grado

    Tumor de células
    redondas

    8811/3

    Fibrosarcoma epitelioide
    esclerosante

    8810/3

    Tumor tipo
    fibrohistocitario

    Benigno

    Tumor de la vaina tendinosa de
    células gigantes

    9252/0

    Células gigantes tipo
    difuso

    9251/0

    Histocitoma fibroso profundo
    benigno

    8830/0

    Intermedio (raramente
    metastatizante)

    Tumor fibrohistocitico
    plexiforme

    8835/1

    Tumor células
    gigantes

    9251/1

    Maligno

    Histocitoma fibroso maligno
    pleomorfico – sarcoma indiferenciado pleomorfico

    8830/3

    Histocitoma fibroso maligno
    células gigantes – sarcoma pleomorfico
    indiferenciado con células gigantes

    8830/3

    Histocitoma fibroso maligno
    inflamatorio – sarcoma pleomorfico indiferenciado con
    inflamación prominente.

    8830/3

    Tumores musculo
    liso

    Angioleiomioma

    8894/0

    Leiomioma profundo

    8890/0

    Leiomioma genital

    8890/0

    Leiomiosarcoma

    8890/3

    Tumores Pericitico
    (perivascular)

    Tumor glomus

    Tumor glomus maligno

    8711/0

    Miopericitoma

    8713/1

    Tumores del musculo
    esquelético

    Benigno

    Rabdomioma

    Tipo adulto

    Tipo fetal

    Tipo genital

    8900/0

    8904/0

    8903/0

    8905/0

    Maligno

    Rabdomiosarcoma embrionario
    (células redondas, botroide, anaplasico)

    8910/3

    8912/3

    8910/3

    Rabdomiosarcoma alveolar (solido,
    anaplasico)

    8920/3

    Rabdomiosarcoma
    pleomorfico

    8901/3

    Tumores vasculares

    Benigno

    Hemangiomas

    • Capilar

    • Cavernoso

    • Arteriovenoso

    • Venoso

    • Intramuscular

    • Sinovial

    9120/0

    9131/0

    9121/0

    9123/0

    9122/0

    9132/0

    9120/0

    Hemangioma epitelioide

    9125/0

    Angiomatosis

    Linfangioma

    9170/0

    Intermedio (localmente
    agresivo)

    hemangioendotelioma
    Kaposiforme

    9130/1

    Intermedio (raramente
    metastatizante)

    Hemangioendotelioma
    retiforme

    9135/1

    Angioendotelioma papilar
    intralinfatico

    9135/1

    Hemangioendotelioma
    compuesto

    9130/1

    Sarcoma de Kaposi

    9140/3

    Maligno

    Hemangioendotelioma
    epitelioide

    9133/3

    Angiosarcoma partes
    blandas

    9120/3

    Tumores condro-
    oseos

    Condroma partes blandas

    9220/0

    Condrosarcoma
    mesenquimatico

    9240/3

    Osteosarcoma
    extraesqueletico

    9180/3

    Tumores de diferenciación
    incierta

    Benigno

    Mixoma intramuscular (incluye
    variedad celular)

    8840/0

    Mixoma yuxta-articular

    8840/0

    Angiomixoma profundo
    (agresivo)

    8841/0

    Tumor angioestasico hialinizante
    pleomorfico

    Thimoma hamartomatoso
    ectópico

    8587/0

    Intermedio (raramente
    metastatizante)

    Histocitoma fibroso
    angiomatoide

    8836/1

    Tumor fibromixoide osificante
    (atípico-maligno)

    8842/0

    Tumor mixoide – mioepitelioma –
    paracondroma

    8940/1

    8982/1

    9373/1

    Maligno

    Sarcoma sinovial

    9040/3

    Sarcoma epitelioide

    8804/3

    Sarcoma partes blandas
    alveolar

    9581/3

    Sarcoma partes blandas células
    claras

    9044/3

    Condrosarcoma mixoide
    extraesqueletico

    9231/3

    PNET/Extraesqueletico Ewing tumor
    PNET

    9364/3

    9260/3

    Tumor desmoplasico de células
    redondas

    8806/3

    Tumor rabdoide extrarenal

    8963/3

    Mesenquimoma maligno

    8990/3

    PEComa. Neoplasma con
    diferenciación celular perivascular epitelioide –
    tumor miomelanocitico células claras

    Sarcoma intimal

    8800/3

    *Código de la clasificación
    internacional de enfermedades oncológicas.

    MONOGRAFIA DE ASISTENTE

    DE CIRUGIA GENERAL

     

     

    Autor:

    Dr Pablo
    Valsangiácomo

    Clínica Quirúrgica 3. Prof Dr
    Luis Ruso.

    Hospital Maciel. Facultad de
    Medicina.

    Montevideo. Uruguay

    Junio 2011

    Partes: 1, 2, 3
     Página anterior Volver al principio del trabajoPágina siguiente 

    Nota al lector: es posible que esta página no contenga todos los componentes del trabajo original (pies de página, avanzadas formulas matemáticas, esquemas o tablas complejas, etc.). Recuerde que para ver el trabajo en su versión original completa, puede descargarlo desde el menú superior.

    Todos los documentos disponibles en este sitio expresan los puntos de vista de sus respectivos autores y no de Monografias.com. El objetivo de Monografias.com es poner el conocimiento a disposición de toda su comunidad. Queda bajo la responsabilidad de cada lector el eventual uso que se le de a esta información. Asimismo, es obligatoria la cita del autor del contenido y de Monografias.com como fuentes de información.

    Categorias
    Newsletter